Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Fougerou-Leurent C"" wg kryterium: Autor


Tytuł:
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.
Autorzy:
Mercier N; ANRS, Maladies Infectieuses Emergentes, Paris, France.; Institut National de la Santé et de la Recherche Médicale, INSERM, Paris, France.
Belhadi D; AP-HP, Hôpital Bichat, Département d'Épidémiologie, Biostatistique et Recherche Clinique, Paris, France.
DeChanet A; Department of Pharmacology, Inserm CIC 1414 and Rennes University Hospital, Rennes, France.
Delmas C; Institut de Santé Publique, Pôle Recherche Clinique, INSERM, Paris, France.
Saillard J; ANRS, Maladies Infectieuses Emergentes, Paris, France.
Dumousseaux M; Institut de Santé Publique, Pôle Recherche Clinique, INSERM, Paris, France.
Le Mestre S; ANRS, Maladies Infectieuses Emergentes, Paris, France.
Fougerou-Leurent C; Department of Pharmacology, Inserm CIC 1414 and Rennes University Hospital, Rennes, France.
Ferrane A; Institut de Santé Publique, Pôle Recherche Clinique, INSERM, Paris, France.
Burdet C; AP-HP, Hôpital Bichat, Département d'Épidémiologie, Biostatistique et Recherche Clinique, Paris, France.; AP-HP, Hôpital Bichat, Unité de Recherche Clinique, Paris, France.; Université de Paris, IAME, INSERM, Paris, France.; AP-HP, Hôpital Bichat, Département d'Épidémiologie, Biostatistique et Recherche Clinique, Paris, France.
Espérou H; Institut National de la Santé et de la Recherche Médicale, INSERM, Paris, France.
Ader F; Hospices Civils de Lyon, Département des Maladies Infectieuses et Tropicales, Lyon, France.; Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, France.
Hites M; L'Hôpital Universitaire de Bruxelles-Hôpital Érasme, Université Libre de Bruxelles, Clinique des Maladies Infectieuses, Brussels, Belgium.
Peiffer-Smadja N; Université de Paris, IAME, INSERM, Paris, France.; AP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, Paris, France.
Poissy J; Université de Lille, Inserm U1285, CHU Lille, Pôle de Réanimation, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, Lille, France.
Andrejak C; CHU d'Amiens, Département de Pneumologie, UR4294 AGIR Picardie Jules Verne University, Amiens, France.
Paiva JA; Department of Critical Care Medicine, Centro Hospitalar Universitário de São João, Porto, Portugal.
Tacconelli E; Division of Infectious Diseases, Diagnostic and Public Health, University of Verona, Verona, Italy.
Staub T; Centre Hospitalier de Luxembourg, Maladies Infectieuses, Luxembourg City, Luxembourg.
Greil R; Paracelsus Medical University Salzburg, Laboratory of Immunological and Molecular Cancer Research, Salzburg, Austria.
Costagliola D; Sorbonne Université, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, INSERM, Paris, France.
Mentre F; AP-HP, Hôpital Bichat, Département d'Épidémiologie, Biostatistique et Recherche Clinique, Paris, France.; AP-HP, Hôpital Bichat, Unité de Recherche Clinique, Paris, France.; Université de Paris, IAME, INSERM, Paris, France.
Yazdanpanah Y; ANRS, Maladies Infectieuses Emergentes, Paris, France.; Université de Paris, IAME, INSERM, Paris, France.; AP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, Paris, France.
Diallo A; ANRS, Maladies Infectieuses Emergentes, Paris, France.; Institut National de la Santé et de la Recherche Médicale, INSERM, Paris, France.
Pokaż więcej
Corporate Authors:
DisCoVeRy Safety Working group
Źródło:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Jun; Vol. 11 (3), pp. e01072.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*
Adult ; Humans ; Pandemics ; Pharmacovigilance ; Communicable Disease Control ; Hydroxychloroquine/adverse effects ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Tytuł:
Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder.
Autorzy:
Lalanne S; Experimental and Clinical Pharmacology Department, CHU Rennes, 35033 Rennes, France.; Inserm, CIC 1414 (Clinical Investigation Center), 35033 Rennes, France.
Fougerou-Leurent C; Experimental and Clinical Pharmacology Department, CHU Rennes, 35033 Rennes, France.; Inserm, CIC 1414 (Clinical Investigation Center), 35033 Rennes, France.
Anderson GM; Child Study Center, Yale University School of Medicine, New Haven, CT 06520, USA.
Schroder CM; Department of Child and Adolescent Psychiatry, Strasbourg University Hospitals, 67000 Strasbourg, France.; CNRS UPR 3212, Institute for Cellular and Integrative Neurosciences, 67000 Strasbourg, France.; Sleep Disorders Center & CIRCSom (International Research Center for ChronoSomnology), Strasbourg University Hospital, 67000 Strasbourg, France.
Nir T; Neurim Pharmaceuticals Ltd., Tel Aviv 69710, Israel.
Chokron S; Integrative Neuroscience and Cognition Center (INCC), CNRS UMR 8002 and University of Paris, 75006 Paris, France.
Delorme R; Child and Adolescent Psychiatry Department, Robert Debré Hospital and University of Paris, 75019 Paris, France.
Claustrat B; Laboratoire d'Hormonologie, Inserm U846, Centre de Médecine Nucléaire, Hospices Civils de Lyon, 69677 Bron, France.
Bellissant E; Experimental and Clinical Pharmacology Department, CHU Rennes, 35033 Rennes, France.; Inserm, CIC 1414 (Clinical Investigation Center), 35033 Rennes, France.; School of Medicine of Rennes, University of Rennes 1, 35000 Rennes, France.
Kermarrec S; Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (PHUPEA), Université de Rennes 1 and Centre Hospitalier Guillaume-Régnier, 35000 Rennes, France.
Franco P; Pediatric Sleep Unit, Inserm U1028, University of Lyon 1, 69000 Lyon, France.
Denis L; Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (PHUPEA), Université de Rennes 1 and Centre Hospitalier Guillaume-Régnier, 35000 Rennes, France.
Tordjman S; Inserm, CIC 1414 (Clinical Investigation Center), 35033 Rennes, France.; Integrative Neuroscience and Cognition Center (INCC), CNRS UMR 8002 and University of Paris, 75006 Paris, France.; Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (PHUPEA), Université de Rennes 1 and Centre Hospitalier Guillaume-Régnier, 35000 Rennes, France.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 02; Vol. 22 (3). Date of Electronic Publication: 2021 Feb 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Autism Spectrum Disorder/*complications
Melatonin/*pharmacokinetics
Sleep Disorders, Intrinsic/*drug therapy
Administration, Oral ; Adult ; Autism Spectrum Disorder/metabolism ; Autism Spectrum Disorder/psychology ; Biological Availability ; Child ; Child, Preschool ; Circadian Rhythm ; Delayed-Action Preparations ; Dietary Supplements ; Female ; Humans ; Injections, Intravenous ; Male ; Melatonin/administration & dosage ; Melatonin/analogs & derivatives ; Melatonin/physiology ; Melatonin/therapeutic use ; Melatonin/urine ; Receptors, Melatonin/physiology ; Saliva/chemistry ; Seasons ; Serotonin/metabolism ; Sleep Disorders, Intrinsic/etiology ; Sleep Disorders, Intrinsic/physiopathology ; Sleep Latency/drug effects ; Social Behavior Disorders/drug therapy ; Social Behavior Disorders/etiology ; Tryptophan/metabolism
Czasopismo naukowe
Tytuł:
Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study.
Autorzy:
Anty R; Nice, France.
Favre G; Nice, France.
Coilly A; Villejuif, France.
Rossignol E; Rennes, France.
Houssel-Debry P; Rennes, France.
Duvoux C; Créteil, France.
De Ledinghen V; Bordeaux, France.
Di Martino V; Besançon, France.
Leroy V; Grenoble, France.
Radenne S; Lyon, France.
Kamar N; Toulouse, France.
Canva V; Lille, France.
D'Alteroche L; Tours, France.
Durand F; Clichy, France.
Dumortier J; Lyon, France.
Lebray P; Paris, France.
Besch C; Strasbourg, France.
Tran A; Nice, France.
Canivet CM; Nice, France.
Botta-Fridlund D; Marseille, France.
Montialoux H; Rouen, France.
Moreno C; Belgique, France.
Conti F; Paris, France.
Silvain C; Poitiers, France.
Perré P; La Roche sur Yon, France.
Habersetzer F; Strasbourg, France.
Abergel A; Clermont-Ferrand, France.
Debette-Gratien M; Limoges, France.
Dharancy S; Lille, France.
Esnault VLM; Villejuif, France.
Fougerou-Leurent C; Rennes, France.
Cagnot C; Clichy, France.
Diallo A; Montpellier, France.
Veislinger A; Rennes, France.
Danjou H; Rennes, France.
Samuel D; Villejuif, France.
Pageaux GP; Montpellier, France.
Duclos-Vallée JC; Villejuif, France.
Pokaż więcej
Corporate Authors:
ANRS CO23 CUPILT Study Group
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Jun; Vol. 47 (12), pp. 1682-1689. Date of Electronic Publication: 2018 Apr 17.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Hepatitis C/*drug therapy
Kidney/*pathology
Liver Transplantation/*methods
Sofosbuvir/*administration & dosage
Aged ; Cohort Studies ; Creatinine/blood ; Female ; Glomerular Filtration Rate ; Hepacivirus/isolation & purification ; Humans ; Longitudinal Studies ; Middle Aged ; Prospective Studies ; Recurrence ; Renal Insufficiency, Chronic/epidemiology ; Ribavirin/administration & dosage ; Sofosbuvir/adverse effects
Czasopismo naukowe
Tytuł:
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Autorzy:
Rosenthal E; Internal Medicine Department, CHU de Nice, Hôpital Archet 1, Nice, France.
Fougerou-Leurent C; Pharmacology Department, CHU Rennes, Rennes, France.; Inserm, CIC1414, Rennes, France.
Renault A; Inserm, CIC1414, Rennes, France.; Pharmacology Laboratory, Faculté de Médecine, Univ Rennes 1, Rennes, France.
Carrieri MP; Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Inserm, IRD, Aix Marseille Univ, Marseille, France.; Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France.
Marcellin F; Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Inserm, IRD, Aix Marseille Univ, Marseille, France.; Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France.
Garraffo R; Clinical Pharmacology and Toxicology Department, CHU de Nice, Nice, France.
Teicher E; Infectious Diseases Department, APHP, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
Aumaitre H; Infectious and Tropical Diseases Department, Hôpital de Perpignan, Perpignan, France.
Lacombe K; Infectious Diseases Department, APHP, Hôpital Saint Antoine, Paris, France.
Bailly F; Hepatology Department, HCL, Hôpital de la Croix-Rousse, Lyon, France.
Billaud E; Infectious Diseases Department, CHU Nantes, Nantes, France.
Chevaliez S; Virology Department, APHP, Hôpital Henri Mondor, Créteil, France.
Dominguez S; Clinical Immunology Department, APHP, Hôpital Henri Mondor, Créteil, France.
Valantin MA; Infectious Diseases Department, APHP, Hôpital La Pitié Salpêtrière, Paris, France.
Reynes J; Infectious Diseases Department, CHU Montpellier, Montpellier, France.
Naqvi A; Infectious Diseases Department, CHU de Nice, Hôpital Archet 1, Nice, France.
Cotte L; Infectious Diseases Department, HCL, Hôpital de la Croix-Rousse, Lyon, France.
Metivier S; Hepatogastroenterology Department, CHU Toulouse, Toulouse, France.
Leroy V; Hepatogastroenterology Department, CHU Grenoble, Grenoble, France.
Dupon M; Infectious Diseases Department, CHU Bordeaux, Bordeaux, France.
Allegre T; Hemato Oncology Department, CH du Pays d'Aix, Aix-en-Provence, France.
De Truchis P; Infectious Diseases Department, APHP, Hôpital R Poincaré, Garches, France.
Jeantils V; Infectious Diseases Department, APHP, Hôpital J Verdier, Bondy, France.
Chas J; Infectious and Tropical Diseases Department, APHP, Hôpital Tenon, Paris, France.
Salmon-Ceron D; Infectious Diseases Department, APHP, Hôpital Cochin, Paris, France.
Morlat P; Internal Medicine and Infectious Diseases Department, CHU Bordeaux, Bordeaux, France.
Neau D; Infectious and Tropical Diseases Department, CHU Bordeaux, Bordeaux, France.
Perré P; Internal Medicine Department, CHD Vendée, La Roche sur Yon, France.
Piroth L; Infectious Diseases Department, CHU Dijon, Dijon, France.
Pol S; Hepato-Gastroenterology Department, APHP, Hôpital Cochin, Paris, France.
Bourlière M; Hepatogastroenterology Department, Hôpital Saint Joseph, Marseille, France.
Pageaux GP; Hepatogastroenterology Department, CHU Montpellier, Montpellier, France.
Alric L; Internal Medicine Department, CHU Toulouse, Toulouse, France.
Zucman D; Internal Medicine Department, Hôpital Foch, Suresne, France.
Girard PM; Infectious Diseases Department, APHP, Hôpital Saint Antoine, Paris, France.
Poizot-Martin I; Immuno and Clinical Hematology department, APHM Sainte-Marguerite, Aix Marseille Univ, Marseille, France.; Inserm U912 (SESSTIM), Marseille, France.
Yazdanpanah Y; Infectious and Tropical Diseases Department, APHP, Hôpital Bichat, Paris, France.
Raffi F; Infectious Diseases Department, CHU Nantes, Nantes, France.
Pabic EL; Pharmacology Department, CHU Rennes, Rennes, France.; Inserm, CIC1414, Rennes, France.
Tual C; Pharmacology Department, CHU Rennes, Rennes, France.; Inserm, CIC1414, Rennes, France.
Pailhé A; Unité de Recherche Clinique et Fondamentale sur les Hépatites Virales, ANRS (France Recherche Nord & Sud Sida-hiv Hépatites), Paris, France.
Amri I; Unité de Recherche Clinique et Fondamentale sur les Hépatites Virales, ANRS (France Recherche Nord & Sud Sida-hiv Hépatites), Paris, France.
Bellissant E; Pharmacology Department, CHU Rennes, Rennes, France.; Inserm, CIC1414, Rennes, France.; Pharmacology Laboratory, Faculté de Médecine, Univ Rennes 1, Rennes, France.
Molina JM; Hepatogastroenterology Department, APHP, Hôpital Saint Louis, Paris, France.
Pokaż więcej
Corporate Authors:
ANRS HC31 SOFTRIH Study Group
Źródło:
HIV medicine [HIV Med] 2018 Mar; Vol. 19 (3), pp. 227-237. Date of Electronic Publication: 2017 Dec 07.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Patient Reported Outcome Measures*
Benzimidazoles/*administration & dosage
Coinfection/*drug therapy
Fluorenes/*administration & dosage
HIV Infections/*drug therapy
Hepatitis C, Chronic/*drug therapy
Sofosbuvir/*administration & dosage
Aged ; Benzimidazoles/adverse effects ; Drug Administration Schedule ; Female ; Fibrosis ; Fluorenes/adverse effects ; Genotype ; HIV Protease Inhibitors/therapeutic use ; HIV-1/genetics ; Hepacivirus/genetics ; Hepatitis C, Chronic/pathology ; Humans ; Male ; Middle Aged ; Pilot Projects ; Sofosbuvir/adverse effects ; Sustained Virologic Response ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies